Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.10 is 55% below its 5-year average of 0.22, near the low end of its 5-year range (-1.05–11.50).
As of the fiscal period ended Tuesday, June 30, 2026. 1.12% above its 12-month average of 0.10.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.10.
DEBT TO EQUITY RATIO
0.10
DEBT TO EQUITY RATIO AVG TTM
0.10
DEBT TO EQUITY RATIO AVG 3Y
0.11
DEBT TO EQUITY RATIO AVG 5Y
0.22
DEBT TO EQUITY RATIO AVG 10Y
0.21
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+1.12%
CURRENT VS 3Y AVG
-16.02%
CURRENT VS 5Y AVG
-55.35%
CURRENT VS 10Y AVG
-53.48%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-12.62%
vs the sector median at left
Wave Life Sciences Ltd.
Market Cap
$689.92M
Debt to Equity Ratio
0.10
TTM Avg
0.10
3Y Avg
0.11
5Y Avg
0.22
Market Cap
$691.32M
Debt to Equity Ratio
0.01
TTM Avg
0.06
3Y Avg
0.15
5Y Avg
0.44
Market Cap
$690.48M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$696.54M
Debt to Equity Ratio
0.00
TTM Avg
0.09
3Y Avg
0.09
5Y Avg
0.07
Market Cap
$680.93M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$679.79M
Debt to Equity Ratio
0.05
TTM Avg
0.15
3Y Avg
0.16
5Y Avg
0.12
Market Cap
$701.24M
Debt to Equity Ratio
0.08
TTM Avg
0.06
3Y Avg
0.05
5Y Avg
0.04
Market Cap
$710.02M
Debt to Equity Ratio
2.75
TTM Avg
3.44
3Y Avg
3.49
5Y Avg
2.78
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Wave Life Sciences Ltd. (WVE) | $689.92M | 0.10 | 0.10 | 0.11 | 0.22 |
| Anteris Technologies Global Corp. (AVR)vs › | $691.32M | 0.01 | 0.06 | 0.15 | 0.44 |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $690.48M | 0.00 | 0.00 | 0.01 | 0.01 |
| Verastem, Inc. (VSTM)vs › | $684.54M | 1.69 | 1.34 | 0.88 | 0.57 |
| Faeth Therapeutics, Inc. (FTH)vs › | $696.54M | 0.00 | 0.09 | 0.09 | 0.07 |
| ArriVent BioPharma, Inc. (AVBP)vs › | $680.93M | 0.00 | 0.00 | 0.00 | 0.00 |
| Solid Biosciences Inc. (SLDB)vs › | $679.79M | 0.05 | 0.15 | 0.16 | 0.12 |
| Cytek Biosciences, Inc. (CTKB)vs › | $701.24M | 0.08 | 0.06 | 0.05 | 0.04 |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $710.02M | 2.75 | 3.44 | 3.49 | 2.78 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $711.74M | 0.00 | 0.01 | 0.03 | 0.31 |
Debt/Equity
0.10
Current Ratio
9.99
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.10 |
| 2026-03-31 | 0.03 |
| 2025-12-31 | 0.03 |
| 2025-09-30 | 0.16 |
| 2025-06-30 | 0.16 |
| 2025-03-31 | 0.14 |
| 2024-12-31 | 0.12 |
| 2024-09-30 | 0.18 |
| 2024-06-30 | 6.57 |
| 2024-03-31 | 1.20 |
| 2023-12-31 | 0.81 |
| 2023-09-30 | -0.83 |
| 2023-06-30 | -0.68 |
| 2023-03-31 | -1.05 |
| 2022-12-31 | -0.83 |
| 2022-09-30 | 11.50 |
| 2022-06-30 | 1.28 |
| 2022-03-31 | 3.67 |
| 2021-12-31 | 0.92 |
| 2021-09-30 | 0.89 |
| 2021-06-30 | 1.26 |
| 2021-03-31 | 0.54 |
| 2020-12-31 | 0.32 |
| 2020-09-30 | 0.28 |
| 2020-06-30 | 9.15 |
| 2020-03-31 | 1.11 |
| 2019-12-31 | 0.45 |
| 2019-09-30 | 0.29 |
| 2019-06-30 | 0.21 |
| 2019-03-31 | 0.18 |
| 2018-12-31 | 0.14 |
| 2018-09-30 | 0.09 |
| 2018-06-30 | 0.05 |
| 2018-03-31 | 0.04 |
| 2017-12-31 | 0.02 |
| 2017-09-30 | 0.02 |
| 2017-06-30 | 0.01 |
| 2017-03-31 | 0.01 |
| 2016-12-31 | 0.00 |
| 2016-09-30 | 0.00 |
| 2016-06-30 | 0.00 |
| 2016-03-31 | 0.00 |
| 2015-12-31 | 0.00 |
| 2015-09-30 | -0.05 |
| 2015-06-30 | 0.02 |
| 2015-03-31 | 0.00 |
| 2014-12-31 | 0.00 |
| 2014-09-30 | 0.00 |
| 2014-06-30 | 0.00 |
| 2014-03-31 | 0.00 |
